Scott Smith Biography and Net Worth

Executive Vice President, Chief Financial Officer of Ascendis Pharma A/S

Scott Smith was named Executive Vice President and Chief Financial Officer at Ascendis Pharma in January 2023, after serving as our Senior Vice President and Chief Financial Officer since August 2016. Prior to joining Ascendis Pharma, Mr. Smith was at Wedbush Securities, where from 2012- 2016 he served as Director of the Healthcare Investment Banking Group at Wedbush Securities, leading the healthcare team, and oversaw a substantial increase in revenue and transaction volume, and from 2009 - 2012, he served as a Managing Director. Prior to Wedbush, Mr. Smith was a Director in the Global Healthcare Investment Banking Group at Merrill Lynch, where he began his career in 1995. He has also worked in sales, marketing and strategy roles for various companies, including start-ups and a Fortune Global 500 company. Mr. Smith received his M.B.A. from the Stanford University Graduate School of Business and his B.A. in Economics/Accounting – Physics (magna cum laude) from Claremont McKenna College.

What is Scott Thomas Smith's net worth?: The estimated net worth of Scott Thomas Smith is at least $949.78 thousand as of June 2nd, 2026. Mr. Smith owns 4,367 shares of Ascendis Pharma A/S stock worth more than $949,779 as of June 3rd. This net worth approximation does not reflect any other investments that Mr. Smith may own. Learn More about Scott Thomas Smith's net worth.
How do I contact Scott Thomas Smith?: The corporate mailing address for Mr. Smith and other Ascendis Pharma A/S executives is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. Ascendis Pharma A/S can also be reached via phone at (457) 022-2244 and via email at [email protected]. Learn More on Scott Thomas Smith's contact information.
Has Scott Thomas Smith been buying or selling shares of Ascendis Pharma A/S?: During the last quarter, Scott Thomas Smith has bought $21,900.00 of Ascendis Pharma A/S stock. Most recently, on Tuesday, June 2nd, Scott Thomas Smith bought 100 shares of Ascendis Pharma A/S stock. The stock was acquired at an average cost of $219.00 per share, with a total value of $21,900.00. Following the completion of the transaction, the chief financial officer now directly owns 4,367 shares of the company's stock, valued at $956,373. Learn More on Scott Thomas Smith's trading history.
Who are Ascendis Pharma A/S's active insiders?: Ascendis Pharma A/S's insider roster includes Jean-Jacques Bienaimé (Director), Flemming Jensen (Insider), and Scott Smith (Executive Vice President, Chief Financial Officer). Learn More on Ascendis Pharma A/S's active insiders.
Are insiders buying or selling shares of Ascendis Pharma A/S?: In the last twelve months, Ascendis Pharma A/S insiders bought shares 2 times. They purchased a total of 500 shares worth more than $117,020.00. In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 19,460 shares worth more than $4,641,015.40. The most recent insider tranaction occured on June, 2nd when CFO Scott Thomas Smith bought 100 shares worth more than $21,900.00. Insiders at Ascendis Pharma A/S own 40.0% of the company. Learn More about insider trades at Ascendis Pharma A/S.
Information on this page was last updated on 6/2/2026.

Scott Thomas Smith Insider Trading History at Ascendis Pharma A/S

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/2/2026	Buy	100	$219.00	$21,900.00	4,367

Scott Thomas Smith Buying and Selling Activity at Ascendis Pharma A/S

Ascendis Pharma A/S Company Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Today's Range

Now: $217.05

$214.17

$218.24

50 Day Range

MA: $233.43

$215.54

$249.84

2 Week Range

Now: $217.05

$160.86

$250.74

Volume

184,064 shs

Average Volume

682,163 shs

Market Capitalization

$13.54 billion

P/E Ratio

24.99

Dividend Yield

N/A

Beta

0.39